Cassava Sciences Q3 net loss narrows, beats expectations

Filana Therapeutics

12/11/2025 13:10

Overview

Cassava Sciences Q3 net loss narrows to $10.8 mln, beating analyst expectations

Company advancing simufilam for TSC-related epilepsy, study planned for H1 2026

Cash and cash equivalents at $106.1 mln, expected to support operations into 2027

Outlook

Cassava plans proof-of-concept study for simufilam in TSC-related epilepsy in H1 2026

Company revises cash use guidance downward for second half of 2025

Cassava expects year-end 2025 cash balance between $92 mln and $96 mln

Result Drivers

COST REDUCTION - Decrease in R&D and G&A expenses contributed to narrowed net loss for Q3 2025

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 EPS
-$0.22
Q3 Net Income
Beat
-$10.81 mln
-$13 mln (1 Analyst)
Q3 Operating Income
Beat
-$11.86 mln
-$14 mln (1 Analyst)
Q3 Basic EPS
-$0.22
Q3 Operating Expenses
$11.86 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Cassava Sciences Inc is $5.00, about 37.8% above its November 11 closing price of $3.11

Press Release: ID:nGNX2XV79r

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)